FR3127043B1 - Mesure in vitro de la lyse d’un caillot de fibrine - Google Patents

Mesure in vitro de la lyse d’un caillot de fibrine

Info

Publication number
FR3127043B1
FR3127043B1 FR2109634A FR2109634A FR3127043B1 FR 3127043 B1 FR3127043 B1 FR 3127043B1 FR 2109634 A FR2109634 A FR 2109634A FR 2109634 A FR2109634 A FR 2109634A FR 3127043 B1 FR3127043 B1 FR 3127043B1
Authority
FR
France
Prior art keywords
fibrin clot
therapeutic treatment
relates
clot lysis
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2109634A
Other languages
English (en)
Other versions
FR3127043A1 (fr
Inventor
Matthieu Daniel Luc Bourdin
Olivier Frédéric Lucien Mathieu
Charlotte Giles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnostica Stago SAS
Original Assignee
Diagnostica Stago SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostica Stago SAS filed Critical Diagnostica Stago SAS
Priority to FR2109634A priority Critical patent/FR3127043B1/fr
Priority to US18/691,193 priority patent/US20250138031A1/en
Priority to PCT/FR2022/051735 priority patent/WO2023041877A1/fr
Priority to JP2024516497A priority patent/JP2024535026A/ja
Publication of FR3127043A1 publication Critical patent/FR3127043A1/fr
Application granted granted Critical
Publication of FR3127043B1 publication Critical patent/FR3127043B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne une méthode de mesure in vitro de la dégradation du caillot de fibrine à partir d’une courbe de lyse d’un caillot de fibrine au cours du temps dans un échantillon de sang ou de plasma préalablement obtenu d’un patient susceptible d’avoir un déficit en au moins un facteur de la coagulation, qui inclus la détermination d’une valeur de niveau basal du caillot de fibrine à un temps t1, et la détermination d’une valeur de niveau dégradé du caillot de fibrine à un temps t2 ultérieur. La méthode peut comprendre une étape supplémentaire de classement de l’échantillon testé dans un groupe reflétant un profil de lyse d’un caillot de fibrine. L’invention concerne également une méthode de suivi d’un traitement thérapeutique administré à un patient susceptible d’avoir ou ayant un déficit en au moins un facteur de coagulation, qui peut également comprendre en outre une étape d’ajustement du traitement thérapeutique suivi par ledit patient, en fonction du classement obtenu. L’invention concerne enclore l’emploi d’acide tranexamique (TXA) ou d’une composition en comprenant pour son utilisation dans un traitement thérapeutique, ladite utilisation comprenant la réalisation d’une méthode selon l’invention, et des moyens pour la mise en œuvre de l’invention.
FR2109634A 2021-09-14 2021-09-14 Mesure in vitro de la lyse d’un caillot de fibrine Active FR3127043B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2109634A FR3127043B1 (fr) 2021-09-14 2021-09-14 Mesure in vitro de la lyse d’un caillot de fibrine
US18/691,193 US20250138031A1 (en) 2021-09-14 2022-09-14 In vitro measurement of the lysis of a fibrin clot
PCT/FR2022/051735 WO2023041877A1 (fr) 2021-09-14 2022-09-14 Mesure in vitro de la lyse d'un caillot de fibrine
JP2024516497A JP2024535026A (ja) 2021-09-14 2022-09-14 フィブリンクロットの溶解のインビトロ測定

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2109634 2021-09-14
FR2109634A FR3127043B1 (fr) 2021-09-14 2021-09-14 Mesure in vitro de la lyse d’un caillot de fibrine

Publications (2)

Publication Number Publication Date
FR3127043A1 FR3127043A1 (fr) 2023-03-17
FR3127043B1 true FR3127043B1 (fr) 2025-11-07

Family

ID=81851041

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2109634A Active FR3127043B1 (fr) 2021-09-14 2021-09-14 Mesure in vitro de la lyse d’un caillot de fibrine

Country Status (4)

Country Link
US (1) US20250138031A1 (fr)
JP (1) JP2024535026A (fr)
FR (1) FR3127043B1 (fr)
WO (1) WO2023041877A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3024237B1 (fr) 2014-07-25 2016-08-05 Stago Diagnostica Methode de determination du profil de structure d'un caillot de fibrine, refletant sa stabilite, pour predire le risque de saignement, de thrombose ou de re-thrombose
WO2016170944A1 (fr) * 2015-04-24 2016-10-27 公立大学法人奈良県立医科大学 Procédé d'évaluation de capacité de coagulation d'échantillon sanguin, et réactif, trousse de réactifs et dispositif à utiliser en son sein
JP7101351B2 (ja) * 2016-04-28 2022-07-15 シスメックス株式会社 血液検体の分析方法、血液検体分析用試薬及び試薬キット、並びに血液検体分析装置

Also Published As

Publication number Publication date
FR3127043A1 (fr) 2023-03-17
WO2023041877A1 (fr) 2023-03-23
JP2024535026A (ja) 2024-09-26
US20250138031A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
Bazzan et al. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients
Nomura et al. A new screening method for periodontitis: an alternative to the community periodontal index
Diler et al. The Child Behavior Checklist (CBCL) and the CBCL-bipolar phenotype are not useful in diagnosing pediatric bipolar disorder
EP2713878B1 (fr) Système de thrombo-élastographie optique et procédé pour l'évaluation de grandeurs de coagulation sanguine
Vita et al. Brain morphology in schizophrenia: a 2‐to 5‐year CT scan follow‐up study
Foroozan et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis
Gill The critical evaluation of laser Doppler imaging in determining burn depth
Haas et al. An age‐adapted approach for the use of D‐dimers in the exclusion of deep venous thrombosis
Otenio et al. Expression of IL-1β, IL-6, TNF-α, and iNOS in pregnant women with periodontal disease
EP4116714A1 (fr) Procédé de mesure de durée de coagulation du sang
Mitra et al. Prospective comparison of point‐of‐care international normalised ratio measurement versus plasma international normalised ratio for acute traumatic coagulopathy
Dundar et al. Recurrent pregnancy loss is associated with increased red cell distribution width and platelet distribution width
González-Quevedo et al. Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension
Parisi et al. The worldwide epidemiology of rosacea.
Ozgonul et al. Accurate use of neutrophil/lymphocyte ratio in patients with age-related macular degeneration
Ou et al. Elevated hemoglobin A2 as a marker for β-thalassemia trait in pregnant women
Greenway et al. Point-of-care monitoring of oral anticoagulation therapy in children
Pastewka et al. Electrophoretic patterns of normal human serums by disc electrophoresis in polyacrylamide gel
FR3024237A1 (fr) Methode de determination du profil de structure d'un caillot de fibrine, refletant sa stabilite, pour predire le risque de saignement, de thrombose ou de re-thrombose
US20240241141A1 (en) System and method for optical detection of hemoglobin variants, oxygen affinity, and deoxygenation
Susetyowati et al. Determining the valid tools to screen malnutrition in cancer patients: a comparison to Patient Generated-Subjective Global Assessment (PG-SGA)
Farnsworth et al. Multi-institution comparison of whole blood potassium hemolysis rates
Zairis et al. C‐reactive protein and rapidly progressive coronary artery disease is there any relation?
Matzelle et al. An audit of the diagnostic accuracy of rotational thromboelastometry for the identification of hypofibrinogenaemia and thrombocytopenia during cardiopulmonary bypass
Morange et al. Ala147Thr and C+ 1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230317

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5